Bristol-Myers Squibb Issues Voluntary Nationwide Recall of COUMADIN (Warfarin Sodium) for Injection Due to Presence of Particulate Matter

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: Bristol-Myers Squibb Issues Voluntary Nationwide Recall of COUMADIN (Warfarin Sodium) for Injection Due to Presence of Particulate Matter

You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

Bristol-Myers Squibb Issues Voluntary Nationwide Recall of COUMADIN (Warfarin Sodium) for Injection Due to Presence of Particulate Matter

07/01/2014 11:34 AM EDT

Bristol-Myers Squibb Company (NYSE:BMY) is voluntarily recalling six lots of COUMADIN FOR INJECTION, 5 mg single-use vials in the U.S. This recall is a precautionary measure based on the company's investigation of visible particulate matter found in a small number of COUMADIN FOR INJECTION unreleased samples.

. For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? Please visit subscriberhelp.govdelivery.com
• Other inquiries? webmail@xxxxxxxxxx

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420